Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Genitourinary cancer updates at ASCO 2023

Toni Choueiri, MD, Dana-Farber Cancer Institute, Boston, MA, shares his anticipations ahead of at the American Society of Clinical Oncology (ASCO) 2023 including a presentation on the latest results from the Phase III CLEAR (NCT02811861) study that established pembrolizumab as the first-line standard of care in renal-cell carcinoma (RCC). This interview took place at ASCO 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.